ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 173 filers reported holding ASCENDIS PHARMA A/S in Q2 2021. The put-call ratio across all filers is 4.45 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $10,811 | +6.3% | 115,454 | +1.3% | 0.03% | +13.0% |
Q2 2023 | $10,170 | -25.4% | 113,952 | -10.4% | 0.02% | -30.3% |
Q1 2023 | $13,629 | -10.9% | 127,116 | +1.5% | 0.03% | -17.5% |
Q4 2022 | $15,290 | -99.9% | 125,198 | +1.8% | 0.04% | +14.3% |
Q3 2022 | $12,694,000 | +0.4% | 122,928 | -9.6% | 0.04% | +2.9% |
Q2 2022 | $12,640,000 | -26.3% | 135,979 | -7.0% | 0.03% | 0.0% |
Q1 2022 | $17,162,000 | -14.7% | 146,231 | -2.2% | 0.03% | -12.8% |
Q4 2021 | $20,120,000 | -18.2% | 149,557 | -3.1% | 0.04% | -22.0% |
Q3 2021 | $24,604,000 | +4.1% | 154,359 | -14.1% | 0.05% | +4.2% |
Q2 2021 | $23,626,000 | +10.5% | 179,603 | +8.2% | 0.05% | +2.1% |
Q1 2021 | $21,389,000 | – | 165,961 | – | 0.05% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Vivo Capital, LLC | 1,797,745 | $265,886,000 | 19.06% |
RA Capital Management | 4,914,955 | $726,922,000 | 14.16% |
Sofinnova Investments, Inc. | 1,109,874 | $164,150,000 | 10.35% |
Eventide Asset Management | 1,709,848 | $252,887,000 | 5.50% |
Asymmetry Capital Management, L.P. | 47,599 | $7,040,000 | 5.39% |
BERYLSON CAPITAL PARTNERS, LLC | 58,200 | $8,608,000 | 5.30% |
Avoro Capital Advisors LLC | 1,750,000 | $258,825,000 | 5.12% |
Eversept Partners, LP | 220,344 | $32,588,878 | 4.47% |
Spyglass Capital Management LLC | 452,104 | $66,866,000 | 4.14% |
Orbimed Advisors | 1,562,986 | $231,166,000 | 3.25% |